Cargando…

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

BACKGROUND: Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Md Yusof, Md Yuzaiful, Arnold, Jack, Saleem, Benazir, Vandevelde, Claire, Dass, Shouvik, Savic, Sinisa, Vital, Edward M, Emery, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873269/ https://www.ncbi.nlm.nih.gov/pubmed/36712951 http://dx.doi.org/10.1016/S2665-9913(23)00004-8

Ejemplares similares

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
por: Pepple, Sophanit, et al.
Publicado: (2022)

Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2022)

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2017)

Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2021)

Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
por: Mahmoud, Khaled, et al.
Publicado: (2019)

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
por: Mahmoud, Khaled, et al.
Publicado: (2021)

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity
por: Psarras, Antonios, et al.
Publicado: (2020)

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity
por: Robinson, James I., et al.
Publicado: (2022)

Single-centre experience of refractory rheumatoid arthritis
por: Fitton, John, et al.
Publicado: (2022)

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
por: Avouac, Jérôme, et al.
Publicado: (2021)

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions
por: Cavagna, Lorenzo, et al.
Publicado: (2014)

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2018)

Current perspective on rituximab in rheumatic diseases
por: Schioppo, Tommaso, et al.
Publicado: (2017)

Neurology of musculoskeletal and rheumatic disorders /
por: Nakano, Kenneth K.
Publicado: (1979)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Advancing frontiers in rheumatic and musculoskeletal imaging
por: Albano, Domenico, et al.
Publicado: (2021)

Single‐Cell RNA‐Sequencing Leading to Breakthroughs in Musculoskeletal Research
por: Ono, Noriaki, et al.
Publicado: (2022)

B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
por: El‐Sherbiny, Yasser M., et al.
Publicado: (2020)

COVID-19 breakthrough infections in rheumatic diseases patients after vaccination
por: Alshukairi, Abeer N., et al.
Publicado: (2022)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
por: Boehnke, Kevin F., et al.
Publicado: (2022)

Priorities for rheumatic and musculoskeletal disease research in Ireland
por: Dorris, Emma R., et al.
Publicado: (2022)

Immune globulin/mycophenolate mofetil/rituximab: Breakthrough COVID-19: 2 case reports
Publicado: (2022)

Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
por: Harrison, Stephanie Rose, et al.
Publicado: (2021)

Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research
por: Fearon, Ursula, et al.
Publicado: (2014)

The Valued Life Activities Scale (VLAs): linguistic validation, cultural adaptation and psychometric testing in people with rheumatic and musculoskeletal diseases in the UK
por: Prior, Y., et al.
Publicado: (2020)

Impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases in the UK: a mixed-methods study
por: Smith, Toby O, et al.
Publicado: (2021)

Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
por: Dumusc, Alexandre, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
por: Berger, Joseph R., et al.
Publicado: (2018)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Accelerometry-Based Activity Recognition and Assessment in Rheumatic and Musculoskeletal Diseases
por: Billiet, Lieven, et al.
Publicado: (2016)

The Third Eye of the Rheumatologist: Applications of Musculoskeletal Ultrasound in Rheumatic Diseases
por: Chen, Hsin-Hua
Publicado: (2017)

Evaluation of physical performance in musculoskeletal and rheumatic diseases with jumping mechanography
por: Dionyssiotis, Yannis, et al.
Publicado: (2019)

Implementation of podiatry telephone appointments for people with rheumatic and musculoskeletal diseases
por: Palmer, J. L., et al.
Publicado: (2021)

Editorial: Psychological impact and quality of life in rheumatic and musculoskeletal diseases
por: Talarico, Rosaria, et al.
Publicado: (2023)

Challenges of translating epidemiologic research: An application to rheumatic and musculoskeletal disorders
por: Lucas, Raquel
Publicado: (2021)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_te374ne7h55ulf2r5jgp8e5kc6